IM-1021
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Malignancies
Conditions
Solid Malignancies, Hematologic Malignancies
Trial Timeline
Feb 26, 2025 → Feb 1, 2029
NCT ID
NCT06823167About IM-1021
IM-1021 is a phase 1 stage product being developed by Immunome for Solid Malignancies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06823167. Target conditions include Solid Malignancies, Hematologic Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06823167 | Phase 1 | Recruiting |
Competing Products
20 competing products in Solid Malignancies